細胞生物学- 細胞生物学部門 -





  1. 1. Iwai Y, Okazaki T, Nishimura H, Kawasaki A, Yagita H, and Honjo T: Microanatomical localization of PD-1 in human tonsils. Immunol. Lett. 83:215, 2002. 
  2.   <抗ヒトPD-1抗体(ニボルマブ原型)の作製>
  3. 2. Freeman GJ*, Long AJ*, Iwai Y*(*はequal contributor), Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, and Honjo T: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.  J. Exp. Med. 192:1027-1034, 2000. 
  4.   <PD-L1の発見>
  1. 3. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno N, Malenkovich N, Nichimura H, Okazaki T, Honjo T, Sharpe AH and Freeman GJ: PD-L2 is a second ligand for PD-1 and inhibits T cell activation.  Nat. Immunol. 3:261-268, 2001. 
  2.   <PD-L2の発見>
  3. 4. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, and Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor  immunotherapy by PD-L1 blockade.  Proc. Natl. Acad. Sci., USA 99:12293-12297, 2002. 
  4.   <PD-L1抗体による抗腫瘍効果、PD-1シグナルを介したがんの免疫逃避機構の発見>
    1. 5. Iwai Y, Terawaki S, and Honjo T: PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17:133-144, 2005. 
    2.   <PD-1抗体によるがん転移の抑制>
      1. 6. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, and Honjo T: PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198:39-50, 2003. 
      2.   <ウイルス感染症におけるPD-1阻害効果>
        1. 7. Iwai Y, Hemmi H, Mizenina O, Kuroda S, Suda, K, and Steinman RM: An IFN-g-IL-18 signaling loop accelerates memory CD8+ T cell proliferation.  PLoS ONE, 3:e2404, 2008. 
        2.   <記憶T細胞誘導モデルの開発>
        3. 8. Kuroda S, Yamazaki M, Abe M, Sakimura K, Takayanagi H, and Iwai Y: Basic leucine zipper transcription factor, ATF-like (BATF) regulates epigenetically and energetically effector CD8 T-cell differentiation via Sirt1 expression. Proc. Natl. Acad. Sci., USA, 108:14885-14889, 2011. 
        4.   <BatfによるキラーT細胞分化制御>
        5. 9. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T: A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 14:1212-1218, 2013. 
        6.   <PD-1研究(基礎研究から臨床応用)についての総説>

      3. 2, 5: Key publication from Press release(The Nobel Prize in Physiology or Medicine 2018)
      4. 3, 4: References from Scientific backgrounds(The Nobel Prize in Physiology or Medicine 2018)


    • Imanishi N, Hirai A, Yoneda K, Shimajiri S, Kuwata T, Tashima Y, Takeuchi M, Iwai Y, Ichiki Y, and Tanaka F.: Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.  J Surg Oncol. 117:1563-1569, 2018.
    • Takeuchi M, Doi T, Obayashi K, Hirai A, Yoneda K, Tanaka F, and Iwai Y: Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunology Letters. 196:155-160, 2018.


    • Miyabe Y, Miyabe C, Mani V, Mempel TR, and Luster AD. Atypical complement receptor C5aR2 transports C5a to initiate neutrophil adhesion and inflammation. Sci Immunol. 4:eaav5951, 2019.